Board of Directors
 |
Erik Nerpin, Chairman of the Board, was born in 1961. Bachelor of Laws, Uppsala University. LL.M.in International Banking Law at Boston University. Nerpin is a lawyer and part-owner of the Kilpatrick Stockton firm of lawyers. Nerpin's activities as a lawyer are focused on stock exchange law, corporate law, and corporate governance. Shareholding: 1,010,000 shares. |
|
 |
Håkan Mellstedt was born in 1942. Professor of oncological biotherapy at the Karolinska Institute since 1999. He is a Doctor of Medicine from the Karolinska Institute in Stockholm. Honorary Chairman of the Board of Directors and member of Kancera's industrial council. Mellstedt has specialized expertise in general internal medicine, hematology and general oncology. In 1999–2010, he was head of the Cancer Centre Karolinska at the Karolinska University Hospital. Shareholding: 974,750 shares. |
|
 |
Bernt Magnusson was born in 1941. Magnusson (M.Pol.Sc.) is the Chairman of the Board at Pharmadule AB and Kwintet AB as well as a member of the Board at a number of companies, including Coor Service Management AB and Pricer AB. Magnusson has long experience of Board assignments in listed companies, and in his Board positions has been engaged in major restructuring of several companies, such as Pharmacia, AssiDomän, NCC, Nordea, Avesta, Swedish Match, Volvo Personvagnar AB, and as CEO at Nordstjernan AB. Magnusson was Chairman of the Board at Skandia in 2004–2005. Shareholding: 200,000 shares, 75,000 options. |
|
 |
Carl-Henrik Heldin was born in 1952. Professor Heldin is since 1986 director of the Ludwig Institute for Cancer Research in Uppsala, and since 1992 professor of molecular cell biology at Uppsala University. He has a solid reputation and extensive network from assignments as advisor to several academic institutions including German Cancer Research Center, Heidelberg, European Institute of Oncology, Milan, European Molecular Biology Laboratory, Heidelberg and the Max Planck Institute in Martinsried. Professor Heldin is also Vice President of the European Research Council. He has over 380 published scientific articles and 190 reviews and has been awarded prestigious research prizes in Sweden, France and the U.S. Professor Heldin is advisor to the biotech companies Kolltan Pharmaceuticals (USA) and MolMed SpA (Italy). |
|
 |
Thomas Olin was born in 1958. CEO of Kancera AB. Ph.D. in physiology and M.Sc. in biology, chemistry and geosciences. Olin has 20 years' experience of both scientific and business management from biotechnology and pharmaceutical companies. He was part of the management group that led the hiving off of Biovitrum from Pharmacia and was later part of the research and business development management at Biovitrum. Olin was responsible for the hiving off of iNovacia from Biovitrum in 2006 and has been CEO at iNovacia since 2006. He also has extensive experience of the licensing of pharmaceutical development projects. Shareholding: 906,300 shares. |
|